Breakthroughs Blog

City of Hope has so many breakthroughs in cancer, diabetes and HIV/AIDS - and so many stories - that we've tailored our blog, Breakthroughs, to provide something for every reader. Whether the breakthroughs are about medical research, treatment advances or personal triumphs, they're all connected.

Breakthroughs - targeting cancer cell master switch
Targeting a cancer cell’s “master switch”

May 9, 2016 | City of Hope

According to a new study published in the prestigious scientific journal, Immunity, scientists at City of Hope have unlocked a key component of STAT3 activation, a gene that has long been associated with tumor cell growth and antitumor immune suppression. By exploring how STAT3 is activated in B cells, a major type of immune cell, our researchers have identified a novel target for cancer therapy.

Continue Reading

Breakthroughs - targeting cancer cell master switch
The role of B cells to target cancer's master switch

May 9, 2016 | City of Hope

In a study published in Immunity, scientists have unlocked a key component of STAT3 activation, a gene that has long been associated with tumor cell growth and anti-tumor immune suppression.

Continue Reading

Marcin Kortylewski, Ph.D., Jeremy Jones, Ph.D. and Sumanta Pal, M.D.
Beating prostate cancer: ‘We’re taking off the brakes’

March 24, 2016 | City of Hope

Researchers at City of Hope believe they are on the verge of significant headway in the treatment of advanced prostate cancer, thanks to new thinking and “staggering” early success.

Continue Reading

Marcin Kortylewski, Ph.D., Jeremy Jones, Ph.D. and Sumanta Pal, M.D.
Taking off the brakes to beat prostate cancer

March 24, 2016 | City of Hope

Researchers believe they are on the verge of significant headway in the treatment of advanced prostate cancer with a focus on immunotherapy and CAR T cell therapy.

Continue Reading

Breakthroughs - antibodies discovery could change cancer treatment - 256x256
Antibodies discovery could revolutionize the treatment of cancer

February 2, 2016 | Elise Lamar

Stat, Myc, Myb, Fos, Ras, and Fox: Those bland monosyllables, unfamiliar to most of us, command the respect and fear of oncologists and cancer researchers worldwide. Why? Because they name proteins that drive uncontrollable cell division, metastasis, and/or drug resistance in numerous cancers.

Continue Reading

Hua Yu
Cancer researcher's work on STAT3 protein gets international recognition

October 4, 2014 | Darrin Joy

Cancer cells are masters of survival. Despite excessive damage to their most basic workings and the constant vigilance of the body’s immune system, they manage to persevere. Hua Yu was recently awarded with the prestigious Humboldt Research Award for her numerous breakthrough discoveries involving  STAT3 .

Continue Reading

Jenny wang
March Grad Student Forum: Jenny Wang

March 21, 2014 | Jenny Wang

Successful breast cancer treatment is often hindered by chemoresistance, metastasis, and tumor recurrence.  The existence of a small population of cells, called cancer stem cells, is thought to contribute to these complications.

Continue Reading

cancer tumor
Scientists uncover important step in tumors' blocking of immune system

March 19, 2014 | Nicole White

Cancers thrive and spread in part because of their ability to create fortresses around themselves that ward off the body’s natural immune defenses, a so-called immunosuppressive microenvironment.  A new study sheds light on how a tumor is able to work against the body's immune system, a discovery with the potential to unlock new immunotherapies.

Continue Reading

prostate cancer
T cell research for prostate cancer gets boost from $1 million gift

February 3, 2014 | Hiu Chung So

Although prostate cancer is often highly treatable, the prognosis for men with metastatic disease remains grim. According to the American Cancer Society, men with distant prostate cancer metastases have a five-year survival rate of 28 percent, and almost 30,000 men die from the disease each year in the United States.

Continue Reading

Load More
Back To Top